Meta-analysis of the relationship between the LOC387715/ARMS2 polymorphism and polypoidal choroidal vasculopathy
1Department of Ophthalmology, Peking University People's Hospital, Beijing, China.
Genetics and Molecular Research : GMR
|January 15, 2013
Summary
The LOC387715/ARMS2 rs10490924 G>T polymorphism is linked to increased risk of polypoidal choroidal vasculopathy (PCV). The GG genotype and T allele significantly elevate PCV susceptibility, particularly in younger patients.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Polypoidal choroidal vasculopathy (PCV) is a significant cause of vision impairment.
- The genetic underpinnings of PCV susceptibility are not fully understood.
- The LOC387715/ARMS2 gene region has been implicated in age-related macular degeneration.
Purpose of the Study:
- To investigate the association between the LOC387715/ARMS2 rs10490924 G>T polymorphism and PCV susceptibility.
- To quantify the genetic risk conferred by different genotypes and alleles of rs10490924 in PCV.
- To explore potential age-related differences in the genetic association.
Main Methods:
- A comprehensive meta-analysis was conducted.
- Data from eight case-control studies, including 1446 PCV cases and 3255 controls, were pooled.
- Pooled odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to assess genetic effects.
Main Results:
- The GG genotype of rs10490924 was significantly associated with elevated PCV risk (OR = 4.23).
- The T allele conferred a 2.09-fold increased likelihood of PCV compared to the G allele (OR = 2.09).
- The genetic association was more pronounced in patients younger than 73 years.
Conclusions:
- The LOC387715/ARMS2 rs10490924 G>T polymorphism is a significant genetic risk factor for PCV susceptibility.
- Specific genotypes (GG) and alleles (T) strongly predispose individuals to developing PCV.
- The findings highlight the importance of this polymorphism in the pathogenesis of PCV, especially in younger populations.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...